Switzerland's MoonLake Q2 net loss narrows as expenses fall - MLTX News | RalliesSwitzerland's MoonLake Q2 net loss narrows as expenses fall
M
MLTX• Expense trends
- EXPENSES DROP - R&D costs were $50.2 mln from $54.5 mln in Q1, while general expenses dropped to $11.4 mln from $15.5 mln in Q1
Key financial details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Loss Per Share | | $0.84 | |
| Q2 Net Loss | | $61.81 mln | |
Outlook and development milestones
- MoonLake expects cash runway to mid-2028
- Company anticipates submitting BLA for sonelokimab in HS by end-Sep. 2026
- MoonLake expects full IZAR-1 Phase 3 trial readout in H1 2027
Quarterly loss narrows as expenses decline
- Switzerland biopharma reported Q2 net loss as operating expenses declined from prior quarter
- Company ended Q2 with $537 mln in cash and expects cash runway to mid-2028
- Phase 3 IZAR-1 trial in psoriatic arthritis met all clinical endpoints at Week 16
GFF
•
